Hikma Pharmaceuticals Plc
The HIK-LN stock trades on London Stock Exchange
Company Description
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 670 (as of 31 December 2021) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 32 manufacturing facilities, 7 R&D centres and 8,700+ employees worldwide.
Drug Pipeline
Source: Hikma Pharmaceuticals Plc - 20220902
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
amiodarone
Tachycardia
Reg/Com
ciprofloxacin
Bacterial Infection
Reg/Com
Granisetron
Nausea and Vomiting
Reg/Com
irinotecan
Bowel Cancer
Reg/Com
Midazolam
Neuropsychiatric Disorders
Reg/Com
0 Comments on HIK-LN stock
Newest
Conversation